Melanoma Clinical Trial
Official title:
Skin Care Behaviors Among Melanoma Survivors and Their Families
| NCT number | NCT02457065 |
| Other study ID # | 00028495 D15090 |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | March 2015 |
| Est. completion date | January 2016 |
| Verified date | December 2018 |
| Source | Dartmouth-Hitchcock Medical Center |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
A patient's sun-related behavior greatly influences the likelihood of that patient developing
melanoma, the most dangerous form of skin cancer. Prior research shows current educational
strategies on inducing preventative behaviors such as wearing sun-protection clothing and
wearing sunscreen are inadequate at effectively changing behavior when used in isolation --
patients are aware of the dangers of not engaging in these preventative measures but forgo
them nonetheless.
The investigators are researching methods to positively influence skin cancer prevention
behaviors among melanoma survivors and their families. The first objective of this study is
to compare patient and familial sun exposure and cancer screening activity before and after a
patient's diagnosis with primary melanoma. The second objective of this study is to note if
hanging a "Melanoma Survivor" plaque in a melanoma survivor's bathroom will significantly
affect the survivor's and broader family's sun exposure and cancer screening activity.
The investigators' sample of patients consists of survivors of primary cutaneous melanoma
less than 4.0 mm in depth who came through the Dermatology Clinic at Dartmouth-Hitchcock
Medical Center and voluntarily chose to participate in the study after being informed of the
nature of the research. These patients completed a confidential survey assessing sun exposure
related activities immediately before and after their diagnosis. After the participants
filled out the survey, the investigators asked the participants if they could nominate a
family member to whom the investigators could explain the purpose of this research study to
and confidentially ask an additional set of questions to evaluate the broader impact of a
melanoma diagnosis. From the investigators' original sample, the investigators randomly chose
a few families who would display the survivor plaque in their primary bathroom. After
six-to-twelve months, during the each patient's follow up visit, the investigators asked the
patient and the patient's nominated family member to fill out another survey to assess sun
exposure related activity.
On the surveys, no names were recorded. Everything was anonymous.
| Status | Completed |
| Enrollment | 54 |
| Est. completion date | January 2016 |
| Est. primary completion date | January 2016 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | N/A and older |
| Eligibility |
Inclusion Criteria: - patient has melanoma diagnosis within past 10 years less than 4mm in depth Exclusion Criteria: |
| Country | Name | City | State |
|---|---|---|---|
| United States | Dartmouth-Hitchcock Medical Center (Heater Road) | Lebanon | New Hampshire |
| Lead Sponsor | Collaborator |
|---|---|
| Dartmouth-Hitchcock Medical Center |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Influence of a Patient's Melanoma Diagnosis on the Survivor's and Broader Family's Skin Cancer Prevention Activity. | Subjects filled out a survey when they enrolled in the study assessing their skin cancer prevention behaviors. Survey questions asked the patient and a family member of theirs to comment on patient and familial sun exposure and cancer screening activity before and after the patient's diagnosis with primary melanoma. Subjects self-reported if the diagnosis changed their behavior. | Collected via a survey administered immediately after a subject enrolled in the study. | |
| Primary | Influence of a "Melanoma Survivor" Plaque on the Survivor's and Broader Family's Skin Cancer Prevention Activity. | Subjects filled out a survey when they enrolled in the study assessing their skin cancer prevention behaviors. The investigators randomly gave some subjects a "Melanoma Survivor" plaque. After 6-12 months, the subjects again filled out a survey assessing their skin cancer prevention behaviors. The investigators analyzed the difference in each subject's responses to the same survey questions over time. The investigators then analyzed the difference between the responses of the subjects who saw the plaque and the subjects who did not see the plaque to discern the influence of the plaque on skin cancer prevention behaviors. Survey questions asked the patient and a family member of theirs to comment on patient and familial sun exposure and cancer screening activity. Subjects self-reported if the their behavior changed over time. | 6-12 months between time of completion of first survey and second survey. |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Completed |
NCT03979872 -
Risk Information and Skin-cancer Education for Undergraduate Prevention
|
N/A | |
| Recruiting |
NCT04986748 -
Using QPOP to Predict Treatment for Sarcomas and Melanomas
|
||
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
| Active, not recruiting |
NCT05470283 -
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
|
Phase 1 | |
| Recruiting |
NCT05077137 -
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
|
Phase 1 | |
| Active, not recruiting |
NCT02721459 -
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
|
Phase 1 | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Recruiting |
NCT05839912 -
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
|
N/A | |
| Recruiting |
NCT04971499 -
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05263453 -
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
|
Phase 2 | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06413680 -
A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT03348891 -
TNF in Melanoma Patients Treated With Immunotherapy
|
N/A | |
| Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
| Completed |
NCT03171064 -
Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment
|
Phase 2 | |
| Not yet recruiting |
NCT05539118 -
Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05171374 -
pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
|
||
| Withdrawn |
NCT02854488 -
Yervoy Pregnancy Surveillance Study
|